

TRIAL RESULTS – 19th JANUARY 2022

[KEYTRUDA® \(pembrolizumab\) Showed Statistically Significant Improvement in DFS vs Placebo as Adjuvant Treatment for Patients With Stage IB-III A NSCLC Regardless of PD-L1 Expression](#)

“KEYTRUDA has become foundational in the treatment of metastatic non-small cell lung cancer and we continue to advance research to explore its potential to help fight cancer earlier,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-III A non-small cell lung cancer. We thank the patients, investigators and our partners at EORTC and ETOP for their important contributions to this study and look forward to sharing these results with the medical community as soon as possible.”

[Updated Clinical Data from Ongoing Ph 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Presented](#)

“NSCLC patients resistant to PD-1/-L1 checkpoint inhibitors (CPIs) have limited treatment options. Current treatment guidelines allow for CPI re-challenge but the overall response rate (ORR) seen with this approach is below 10% and disease control rate (DCR) of up to 45%. Thus, it is encouraging to report that in Part B of the study, the documented ORR has now increased to 15.4 % and DCR has reached 46% in the first 13 evaluable patients treated with ADXS-503 as an add-on therapy at progression with pembrolizumab,” said Dr. Jonathan W. Goldman, Associate Professor of UCLA Hematology and Oncology, Associate Director of Drug Development and Director of Clinical Trials in Thoracic Oncology at UCLA Medical Center in Santa Monica, California. “These results now include a second additional patient with a partial response and 4 patients with stable disease. The durable nature of disease control is also encouraging and includes two patients with ongoing partial responses for 702 and 189 days, and three patients with stable disease sustained for 448, 175 and 117 days.”

[Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers Announced](#)

Alpha Tau CEO Uzi Sofer remarked, "Alpha Tau is incredibly focused on the US market, which we see as the paramount market for the Alpha DaRT. We have been successful thus far in demonstrating promising results around the world, but it was critical for us to generate data such as this in the US as well, and we are very excited by the efficacy and safety data observed. The data from this trial gives us tremendous confidence and brings us closer to the U.S. multi-center pivotal trial for skin cancer, which we are currently planning for 2022, and for which we are already seeing enormous interest from leading clinicians and trial sites in the U.S. and around the world."